Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6913720 | 0.86 | CYP1A2 (0.54) | ALDH1A1KDM4ECYP1A2CYP2C9HTT | |
| SCHEMBL1352439 | 0.86 | ALDH1A1 (0.47) | ALDH1A1KDM4ECYP1A2CYP2C9HTT | |
| SCHEMBL9623873 | 0.84 | CYP1A2 (0.46) | ALDH1A1CYP1A2CYP2C9HTTL3MBTL1 | |
| SCHEMBL8069745 | 0.79 | ALDH1A1 (0.39) | ALDH1A1KDM4EHTTL3MBTL1GAA | |
| SCHEMBL1352690 | 0.79 | CYP2C9 (0.35) | ALDH1A1KDM4ECYP1A2CYP2C9HTT | |
| SCHEMBL6774136 | 0.77 | KDM4E (0.38) | ALDH1A1KDM4E | |
| SCHEMBL5475667 | 0.77 | KDM4E (0.38) | ALDH1A1KDM4E | |
| SCHEMBL18389245 | 0.76 | KDM4E (0.34) | ALDH1A1KDM4E | |
| SCHEMBL24456484 | 0.75 | KDM4E (0.36) | ALDH1A1KDM4E | |
| SCHEMBL16977515 | 0.75 | KDM4E (0.36) | ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210353781-A1 | SURFACE-MODIFIED CELLS, METHODS OF MAKING AND USING | UNITED STATES GOVERNMENT | 2021-11-18 | — | — | US | disclosed |
| WO-2021223736-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2021-11-11 | — | — | WO | disclosed |
| US-11046679-B2 | Indoleamine 2,3-dioxygenase inhibitor and application | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2021-06-29 | — | — | US | disclosed |
| US-20200181131-A1 | INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR AND APPLICATION | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2020-06-11 | — | — | US | disclosed |
| WO-2019075367-A1 | PKM2 ACTIVATORS IN COMBINATION WITH REACTIVE OXYGEN SPECIES FOR TREATMENT OF CANCER | TOLERO PHARMACEUTICALS, INC. (US) | 2019-04-18 | — | — | WO | disclosed |
| US-20180078545-A1 | METHODS FOR TREATING CANCER WITH TRKA RECEPTOR TYROSINE KINASE ANTAGONISTS | VM Oncology LLC (US) | 2018-03-22 | — | — | US | disclosed |
| EP-2909181-B1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | TOLERO PHARMACEUTICALS INC (US) | 2017-08-09 | — | — | EP | disclosed |
| US-20170015631-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2017-01-19 | — | — | US | disclosed |
| US-9394257-B2 | PKM2 modulators and methods for their use | TOLERO PHARMACEUTICALS, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| WO-2016090285-A1 | 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| US-9302988-B2 | Fluoromethyl-substituted pyrrole carboxamides | Grünenthal GmbH (DE) | 2016-04-05 | — | — | US | disclosed |
| US-20150344436-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | SUMITOMO PHARMA ONCOLOGY, INC. | 2015-12-03 | — | — | US | disclosed |
| US-20140066426-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES | GRUENENTHAL GMBH (DE) | 2014-03-06 | — | — | US | disclosed |
| US-20120058997-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046679-B2 | Indoleamine 2,3-dioxygenase inhibitor and application | IDO1, IDO2, INMT | ALDH1A1 1320/4885KDM4E 428/4885CYP1A2 107/4885 |
| US-20180078545-A1 | METHODS FOR TREATING CANCER WITH TRKA RECEPTOR TYROSINE KINASE ANTAGONISTS | NGFR, LCK, ERBB2 | ALDH1A1 3573/4885KDM4E 2732/4885CYP1A2 3835/4885 |
| US-20120058997-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | ALDH1A1 1698/4885KDM4E 1257/4885CYP1A2 1762/4885 |
| US-20140066426-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES | TRPV1, CACNA1B, CACNA1G | ALDH1A1 3161/4885KDM4E 808/4885CYP1A2 2188/4885 |
| US-20210353781-A1 | SURFACE-MODIFIED CELLS, METHODS OF MAKING AND USING | CD4, EPCAM, CD2 | ALDH1A1 3890/4885KDM4E 3171/4885CYP1A2 4884/4885 |
| US-20170015631-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | PDK1, PDK2, PKM | ALDH1A1 2333/4885KDM4E 297/4885CYP1A2 2145/4885 |
| US-20150344436-A1 | PKM2 MODULATORS AND METHODS FOR THEIR USE | PDK1, PDK2, PKM | ALDH1A1 2333/4885KDM4E 297/4885CYP1A2 2145/4885 |
| US-20200181131-A1 | INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR AND APPLICATION | IDO1, IDO2, INMT | ALDH1A1 1320/4885KDM4E 428/4885CYP1A2 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.